Literature DB >> 21868548

Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma.

Kazutoshi Okabe1, Toru Beppu, Katsuki Haraoka, Yoshihiro Oh-Uchida, Sadahiro Yamamura, Shinjiro Tomiyasu, Tsuyoshi Yamanaka, Osamu Sano, Toshiro Masuda, Akira Chikamoto, Shigetoshi Fujiyama, Hideo Baba.   

Abstract

AIM: To determine the safety and usefulness of a novel anticancer drug, miriplatin, in transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma. PATIENTS AND METHODS: Patients (n=115) who underwent TACE with miriplatin-lipiodol suspension (miriplatin group), and control patients (n=131) who underwent TACE with cisplatin-lipiodol suspension (CDDP group) took part in this study.
RESULTS: The overall incidence of adverse events was significantly lower in the miriplatin group. The percentage of patients attaining treatment effect 4 in both groups was not significantly different. The proportion exhibiting a >50% decrease in positive tumor markers following TACE was significantly greater in the CDDP group for alpha-fetoprotein, but not significantly different for des-gammma-carboxy prothrombin.
CONCLUSION: Miriplatin-lipiodol suspension was associated with reduced intensity of adverse events and had comparable short-term therapeutic effects to cisplatin-lipiodol suspension, thereby indicating its usefulness in TACE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21868548

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Authors:  Anne Hulin; Jeanick Stocco; Mohamed Bouattour
Journal:  Clin Pharmacokinet       Date:  2019-08       Impact factor: 6.447

2.  Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.

Authors:  Hideaki Takeyama; Toru Beppu; Takaaki Higashi; Takayoshi Kaida; Kota Arima; Katsunobu Taki; Katsunori Imai; Hidetoshi Nitta; Hiromitsu Hayashi; Shigeki Nakagawa; Hirohisa Okabe; Daisuke Hashimoto; Akira Chikamoto; Takatoshi Ishiko; Motohiko Tanaka; Yutaka Sasaki; Hideo Baba
Journal:  Surg Today       Date:  2017-11-07       Impact factor: 2.549

3.  Preparation and evaluation of reduction-responsive nano-micelles for miriplatin delivery.

Authors:  Ying Zhang; Dejian Hu; Shangcong Han; Guowen Yan; Chao Ma; Chen Wei; Miao Yu; Dongmei Li; Yong Sun
Journal:  Exp Biol Med (Maywood)       Date:  2016-01-06

4.  Short-term therapeutic effects of transcatheter arterial chemoembolization using miriplatin-lipiodol suspension for hepatocellular carcinoma.

Authors:  Sota Oguro; Subaru Hashimoto; Tomoki Tanaka; Masanori Inoue; Seishi Nakatsuka; Sachio Kuribayashi; Keiko Asakura; Shigeyuki Kawachi; Minoru Tanabe; Yuko Kitagawa; Hirotoshi Ebinuma; Hidetsugu Saito; Toshifumi Hibi
Journal:  Jpn J Radiol       Date:  2012-08-28       Impact factor: 2.374

5.  Over-expression of VEGF and MMP-9 in residual tumor cells of hepatocellular carcinoma after embolization with lipidol.

Authors:  Yu-Long Shi; Tao Xu; Le-Ping Li; Xiao-Ping Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-02-08

6.  Improved efficacy of transcatheter arterial chemoembolization using warmed miriplatin for hepatocellular carcinoma.

Authors:  Daisuke Yasui; Satoru Murata; Shiro Onozawa; Takahiko Mine; Tatsuo Ueda; Fumie Sugihara; Chiaki Kawamoto; Eiji Uchida; Shin-ichiro Kumita
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411

7.  Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin.

Authors:  Jin Iwazawa; Shoichi Ohue; Naoko Hashimoto; Takashi Mitani
Journal:  Cancer Manag Res       Date:  2012-04-19       Impact factor: 3.989

8.  Effect of transarterial chemoembolization with miriplatin plus epirubicin on local control of hepatocellular carcinoma: a retrospective comparison with miriplatin monotherapy.

Authors:  Naoko Hashimoto; Jin Iwazawa; Shoichi Ohue; Takashi Mitani
Journal:  Onco Targets Ther       Date:  2013-08-01       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.